SameerDesaiMD(He/Him)

Oncology • Somerset, NJ

Gastrointestinal Cancer, Gynecologic Cancer, Hematologic Oncology

Physician

Join to view full profile

Dr. Desai is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Desai's full profile

Already have an account?

Office
75 Veronica Avenue
Suite 201
Somerset, NJ 08873
Phone+1 732-390-7750

Fax+1 732-390-7725
Is this information wrong?

Education & Training

University of Michigan Health SystemFellowship, Hematology and Medical Oncology, 2004 - 2007
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1995 - 1998
Yale School of MedicineClass of 1995

Certifications & Licensure

NJ State Medical License 2007 - 2025
VA State Medical License 1999 - 2008
MI State Medical License 2004 - 2007
MD State Medical License 1999 - 2002
MA State Medical License 1998 - 2001
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Top Docs New Jersey Jersey Choice, 2012-2023

Clinical Trials

A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer. Start of enrollment: 2021 Dec 22
Withdrawn
Phase 1, Phase 2
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations Start of enrollment: 2022 Mar 04
Recruiting
Phase 3
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer Start of enrollment: 2023 Jan 24
Recruiting
Phase 1, Phase 2
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies Start of enrollment: 2022 Feb 01
Recruiting
Phase 2
A Study to Learn About a New Medicine Called ARV-471 (PF-07850327) in People Who Have Advanced Metastatic Breast Cancer. Start of enrollment: 2023 Mar 03
Recruiting
Phase 3
A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer Start of enrollment: 2021 Sep 15
Recruiting
Phase 1, Phase 2
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer) Start of enrollment: 2020 Oct 09
Active, not recruiting
Phase 3
A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2020 Aug 24
Active, not recruiting
Phase 3
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07) Start of enrollment: 2023 Jan 11
Recruiting
Phase 3
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure Start of enrollment: 2021 Nov 17
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

35 citations
Phase I Study of Oxaliplatin, Full-Dose Gemcitabine, and Concurrent Radiation Therapy in Pancreatic Cancer
Sameer P. Desai, Edgar Ben-Josef, Daniel P. Normolle, Isaac R. Francis, Joel K. Greenson, Diane M. Simeone, Alfred E. Chang, Lisa M. Colletti, Theodore S. Lawrence, Ma...> ;Journal of Clinical Oncology. 2007 Oct 10
20 citations
A phase II study of preoperative capecitabine and radiation therapy in patients with rectal cancer.
Sameer P. Desai, Basil F. El-Rayes, Edgar Ben-Josef, Joel K. Greenson, James A. Knol, Emina Huang, Kent A. Griffith, Philip A. Philip, Cornelius J. McGinn, Mark M. Zal...> ;American Journal of Clinical Oncology. 2007 Aug 1